| Molly Hospelhorn, | |
|
2139 Auburn Ave, Cincinnati, OH 45219-2906 | |
| (937) 554-0519 | |
| Not Available |
| Full Name | Molly Hospelhorn |
|---|---|
| Gender | Female |
| Speciality | Anesthesiology Assistant |
| Experience | 4 Years |
| Location | 2139 Auburn Ave, Cincinnati, Ohio |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1720619802 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367H00000X | Anesthesiologist Assistant | (* (Not Available)) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Christ Hospital | Cincinnati, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Anesthesia Associates Of Cincinnati, Inc | 4789598509 | 115 |
News Archive
"In mid-July, ... the near-final draft of the independent evaluation of the Affordable Medicines Facility - Malaria (AMFm) was released," Victoria Fan, a research fellow at the Center for Global Development (CGD), and Heather Lanthorn, a doctoral candidate at Harvard School of Public Health, write in this post in the center's "Global Health Policy" blog.
According to health experts, Vuvuzelas - the horns used by football fans celebrating last year's World Cup - not only cause noise pollution but may also spread diseases. According to a new study published in PLoS One journal it is seen that a short burst on the instrument creates a spittle shower similar to a sneeze, travelling at a four million droplets a second. Authors write that in crowded venues one person blowing a Vuvuzela could infect many others with airborne illness like the flu or TB.
KemPharm, Inc. today announced that it has commenced a Phase 1 clinical trial in healthy volunteers of its novel prodrug compound, KP106, which is in development for the treatment of attention-deficit hyperactivity disorder (ADHD). KP106, a new chemical entity (NCE) composed of d-amphetamine and a ligand, is the lead investigational candidate from KemPharm's proprietary ligand activated therapy (LAT) platform, which creates improved versions of FDA-approved drugs. KemPharm began the KP106 program in 2007 and has initiated the Phase 1 clinical trial of this candidate in less than 24 months.
ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today reported financial results for the three-month period and fiscal year ended June 30, 2011.
› Verified 5 days ago
| Entity Name | Anesthesia Associates Of Cincinnati, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316945173 PECOS PAC ID: 4789598509 Enrollment ID: O20031117000374 |
News Archive
"In mid-July, ... the near-final draft of the independent evaluation of the Affordable Medicines Facility - Malaria (AMFm) was released," Victoria Fan, a research fellow at the Center for Global Development (CGD), and Heather Lanthorn, a doctoral candidate at Harvard School of Public Health, write in this post in the center's "Global Health Policy" blog.
According to health experts, Vuvuzelas - the horns used by football fans celebrating last year's World Cup - not only cause noise pollution but may also spread diseases. According to a new study published in PLoS One journal it is seen that a short burst on the instrument creates a spittle shower similar to a sneeze, travelling at a four million droplets a second. Authors write that in crowded venues one person blowing a Vuvuzela could infect many others with airborne illness like the flu or TB.
KemPharm, Inc. today announced that it has commenced a Phase 1 clinical trial in healthy volunteers of its novel prodrug compound, KP106, which is in development for the treatment of attention-deficit hyperactivity disorder (ADHD). KP106, a new chemical entity (NCE) composed of d-amphetamine and a ligand, is the lead investigational candidate from KemPharm's proprietary ligand activated therapy (LAT) platform, which creates improved versions of FDA-approved drugs. KemPharm began the KP106 program in 2007 and has initiated the Phase 1 clinical trial of this candidate in less than 24 months.
ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today reported financial results for the three-month period and fiscal year ended June 30, 2011.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Molly Hospelhorn, 4895 Oakland Dr, Lyndhurst, OH 44124-2332 Ph: (937) 554-0519 | Molly Hospelhorn, 2139 Auburn Ave, Cincinnati, OH 45219-2906 Ph: (937) 554-0519 |
News Archive
"In mid-July, ... the near-final draft of the independent evaluation of the Affordable Medicines Facility - Malaria (AMFm) was released," Victoria Fan, a research fellow at the Center for Global Development (CGD), and Heather Lanthorn, a doctoral candidate at Harvard School of Public Health, write in this post in the center's "Global Health Policy" blog.
According to health experts, Vuvuzelas - the horns used by football fans celebrating last year's World Cup - not only cause noise pollution but may also spread diseases. According to a new study published in PLoS One journal it is seen that a short burst on the instrument creates a spittle shower similar to a sneeze, travelling at a four million droplets a second. Authors write that in crowded venues one person blowing a Vuvuzela could infect many others with airborne illness like the flu or TB.
KemPharm, Inc. today announced that it has commenced a Phase 1 clinical trial in healthy volunteers of its novel prodrug compound, KP106, which is in development for the treatment of attention-deficit hyperactivity disorder (ADHD). KP106, a new chemical entity (NCE) composed of d-amphetamine and a ligand, is the lead investigational candidate from KemPharm's proprietary ligand activated therapy (LAT) platform, which creates improved versions of FDA-approved drugs. KemPharm began the KP106 program in 2007 and has initiated the Phase 1 clinical trial of this candidate in less than 24 months.
ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today reported financial results for the three-month period and fiscal year ended June 30, 2011.
› Verified 5 days ago
Maggie Scheler, AA Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 2139 Auburn Ave, Cincinnati, OH 45219 Phone: 513-585-2422 | |
Mr. Alexander Healy Montavon, AA-C Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 2139 Auburn Ave, Cincinnati, OH 45219 Phone: 513-585-2422 Fax: 513-585-3245 | |
Jeffrey Cole Mumpower, CAA Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 2139 Auburn Ave, Cincinnati, OH 45219 Phone: 513-585-2422 Fax: 513-585-3245 | |
Deontay William Walker, Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 2139 Auburn Ave, Cincinnati, OH 45219 Phone: 513-585-2000 | |
Christopher Caldwell, RN Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 2139 Auburn Ave, Cincinnati, OH 45219 Phone: 513-672-3309 Fax: 513-672-3323 | |
Robert R Mccann, AA Anesthesiologist Assistant Medicare: Medicare Enrolled Practice Location: 2139 Auburn Ave, Cincinnati, OH 45219 Phone: 513-672-3309 Fax: 513-672-3323 | |
Christina L Becker, CAA Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 2139 Auburn Ave, Cincinnati, OH 45219 Phone: 513-672-3309 Fax: 513-672-3323 |